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Commentary: Preconceptions about the neurosurgical management of brain metastases 
Messrs Kennion and Holliman report on the "Outcome after craniotomy for recurrent cranial 
metastases" in this month’s journal. In this small but pragmatic report some patients survived more 
30 months after a second craniotomy with a median survival of almost 8 months. There are certainly 
risks in this approach, with some serious complications also seen but the key factors predicting a 
good outcome were performance status and the primary cancer status. Brain metastases are 
currently undergoing something of a paradigm shift in the way in which they are managed.  The 
historically nihilistic approach giving way to a more pragmatic neurosurgical attitude in which our 
role is to maintain the patient in a neurologically sound state with good control of their brain 
disease, whilst treatment of the extracranial cancer continues uninterrupted. Indeed, there is an 
international recognition that this vast problem has been under-resourced and investigated with 
more trials and scientific study urgently needed (www.brain-mets.com). Attend any given neuro-
oncology MDT and it is obvious how often and how numerously these patients present as 
emergency referrals or from the primary cancer oncologists. This new paradigm is leading to 
patients being diagnosed by screening MRI whilst still asymptomatic, and requests for repeat 
resection/biopsy to assess HER2 or BRAF pathway sensitivity to direct targeted therapies. As 
elsewhere in the speciality, preservation of function and thence quality survival is crucial, so if fMRI, 
awake craniotomy, tractography and mapping are applied to glioma, why not to brain metastases? 
 Next the surgical obsession with the number of metastases needs to be dispensed with and instead 
the overall volume (burden) of disease considered, since the patients with the fabled “solitary 
metastasis” may do no better than another with a large dominant metastasis that is resected and 
smaller tumours that are almost immediately irradiated and chemotherapy started. Such hybrid 
approaches will become the new normal and a variety of radiotherapy techniques, including 
hippocampal sparing whole brain irradiation, are being trialled 
(https://clinicaltrials.gov/ct2/show/NCT02147028). Likewise even for the patient with a solitary 
metastasis, can we do better by performing supramarginal resection1,2? Or should we be asking for 
post-operative stereotactic radiosurgery/radiotherapy to the resection cavity? 
(https://clinicaltrials.gov/ct2/show/NCT01372774)  
Finally, as demonstrated by the accompanying paper, the threshold for operating on already 
irradiated and treated cases may have to be lowered in patients who are systemically and 
neurologically well; neoadjuvant type approaches in which immunotherapy or targeted therapies are 
given pre-operatively may change the tumour burden in favour of intervention and the synergistic 
effects of surgery, chemotherapy and radiotherapy are being reported and trialled (see 
http://www.breastcancer.org/treatment/clinical_trials/metastatic-trials-tool). What will be needed 
from the neurosurgical community? Flexibility, a willingness to review patients and assess 
“performance status” first hand, close liaison with interested, motivated oncologists (especially in 
brain tropic cancers such as breast and melanoma), ready access to technologies like SRS and 
familiarity with the  emerging oncology and radiotherapy trends which may only come from 
subspecialist training and fellowships.  
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